Kezar Life Sciences

KEZAR LIFE SCIENCES INC

Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.

Doctor,Demonstrating,Model,Of,Liver,At,Table,In,Clinic,,Closeup

Biotech

News

Health Care

General

Kezar Life Sciences reports positive Phase 2a data for zetomipzomib in autoimmune hepatitis, showing higher response rates and reduced steroid use.

Kezar Life Sciences Touts Positive Data From Mid-Stage Study For Chronic Liver Disease Drug Candidate

Movers

Kezar Life Sciences halted its PALIZADE Phase 2b lupus nephritis trial due to fatal adverse events. Meanwhile, its PORTOLA Phase 2a autoimmune hepatitis trial progresses, with topline data expected in 2025. Kezar also rejected a buyout proposal from Concentra Biosciences.

Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study

movers image

Pre-Market Outlook

Markets

Trading Ideas

ALTM

AMBO

CTCX

ICCT

INAB

LDTC

MLEC

NMHI

OTRK

PALT

PLBY

RMCO

TIGR

Why Saratoga Investment Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

Kezar Life Sciences Inc

Press Releases

Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis

Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal

Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update

Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan

Kezar Life Sciences Announces 1-for-10 Reverse Stock Split

Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR)

Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025

Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025

Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Akari Therapeutics Plc - American Depositary Shares

Akari Therapeutics

Aligos Therapeutics

Allakos

Annovis Bio

BioAtla

bluebird bio

Burning Rock Biotech Limited - American Depositary Shares

Burning Rock Biotech

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics

CASI Pharmaceuticals, Inc. - Ordinary Shares

CASI Pharmaceuticals

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics

Dyadic International, Inc. - Common Stock

Dyadic International

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

FibroBiologics

FibroGen

Generation Bio

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics

Werewolf Therapeutics, Inc. - Common Stock

Werewolf Therapeutics

MiNK Therapeutics

OnKure Therapeutics, Inc. - Class A Common Stock

OnKure Therapeutics

OSR Holdings

Radiopharm Theranostics Limited - American Depositary Shares

Radiopharm Theranostics

Spero Therapeutics

Surrozen

Xilio Therapeutics

Wells Fargo

Comments

Kezar Life Sciences

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell